Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5 R,6 R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane

European Journal of Pharmacology

Volumn 356, Issue 2-3, 1998, Pages 109-119

  Bymaster, Frank P ^a   Shannon, Harlan E ^a   Rasmussen, Kurt ^a   Delapp, Neil W ^a   Mitch, Charles H ^a   Ward, John S ^a   Calligaro, David O ^a   Ludvigsen, Thomas S ^b   Sheardown, Malcolm J ^b   Olesen, Preben H ^b   Swedberg, Michael D B ^b   Sauerberg, Per ^b   Fink Jensen, Anders ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Antipsychotic; Conditioned avoidance responding; Fos protein immunoreactivity; Muscarinic receptor; Schizophrenia; Single unit recording

Indexed keywords

APOMORPHINE; BICYCLO[3.2.1]OCTANE DERIVATIVE; DEXAMPHETAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CATALEPSY; CHO CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; IMMUNOREACTIVITY; LOCOMOTION; MALE; NERVE CELL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SCHIZOPHRENIA; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; AVOIDANCE LEARNING; BICYCLO COMPOUNDS; BRAIN; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; LIGANDS; MALE; MICE; MOTOR ACTIVITY; MUSCARINIC ANTAGONISTS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; RECEPTORS, MUSCARINIC; SCOPOLAMINE; SECOND MESSENGER SYSTEMS; THIADIAZOLES;

EID: 0031786012     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00487-7     Document Type: Article

References (27)

1. Andersen, P.H., 1989. The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur. J. Pharmacol. 166, 493-504.
2. Arnt, J., 1982. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol. Toxicol. 51, 321-329.
3. 1-transfected A9L cells. Cell. Signal. 7, 39-43.
4. Beckmann, B., Hippius, H., Reuter, E., 1979. Treatment of schizophrenia. Prog. Neuro-Psychopharmacol. 3, 47-52.
5. Carlsson, A., Hansson, L.O., Waters, N., Carlsson, M.L., 1997. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sciences 61, 75-94.
6. Chalmers, R.K., Erickson, C.K., 1964. Central cholinergic blockade of the conditioned avoidance response in rats. Psychopharmacology 6, 31-41.
7. Chiodo, L.A., Bunney, B.S., 1983. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 dopaminergic neurons. J. Neurosci. 3, 1609-1619.
8. Costall, B., Naylor, R.J., Nohria, V., 1978. Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity. Eur. J. Pharmacol. 50, 39-50.
9. 2 receptor blockade to haloperidol. Neurosci. Lett. 194, 77-80.
10. Fuller, R.W., Perry, K.W., 1989. Effects of buspirone and its metabolite, l-(2-pyrimidinyl)piperazine, on brain monoamines and their metabolites in rats. J. Pharmacol. Exp. Ther. 248, 50-56.
11. Harper, J.F., Brooker, G., 1975. Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2′0 acetylation by acetic anhydride in aqueous solution. J. Cyclic Nucleotide Res. 1, 207-218.
12. 5 receptor. J. Recept. Res. 13, 573-590.
13. Karson, C.N., Casanova, M.F., Kleinman, J.E., Griffin, W.S.T., 1993. Choline acetyltransferase in schizophrenia. Am. J. Psychiatry 150, 454-459.
14. Levey, A.I., Kitt, C.A., Simonds, W.F., Price, D.L., Brann, M.R., 1991. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci. 11, 3218-3226.
15. Morgan, J., Curran, T., 1989. Stimulus-transcription coupling in neurons: role of cellular immediate-early genes. Trends Neurosci. 12, 459-462.
16. Pfeiffer, C.C., Jenney, E.H., 1957. The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain. Ann. New York Acad. Sci. 66, 653-664.
17. Sagar, S.M., Sharp, F.R., Curran, T., 1989. Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science 240, 1328-1331.
18. 4 receptors bind inactive (+)-apomorphines, suggesting neuroleptic role: sulpiride not stereoselective. Eur. J. Pharmacol. 233, 173-174.
19. Seeman, P., Lee, T., Chau-Wong, M., Wong, K.P., 1976. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261, 717-719.
20. Stockton, M.E., Rasmussen, K., 1996. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 14, 97-104.
21. Suzdak, P.D., Fredricksen, K., Andersen, K.E., Sørensen, P.O., Knutsen, L.J.S., Nielsen, E.B., 1992. NNC-711, a novel potent and selective gamma-aminobutyric acid uptake inhibitor: a pharmacological characterization. Eur. J. Pharmacol. 224, 189-198.
22. Verhave, T., Owen, J.E., Slater, O.H., 1958. Effects of various drugs on escape and avoidance behavior. Prog. Neurobiol. 3, 267-301.
23. Westerink, B.H., Korf, J., 1976. Regional rat brain levels of 3,4-dihydroxyphenyl-acetic acid and homovanillic acid: concurrent fluorometric measurement and influence of drugs. Eur. J. Pharmacol. 38, 281-291.
24. White, K.E., Cummings, J.L., 1996. Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies. Compr. Psychiatry 37, 188-195.
25. White, F.J., Wang, R.Y., 1983. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221, 1054-1057.
26. Yeomans, J.S., 1995. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 12, 3-16.
27. Zilles, K., Schroder, H., Schroder, U., Horvath, E., Werner, L., Luiten, P.G., Maelicke, A., Strosberg, A.D., 1989. Distribution of cholinergic receptors in the rat and human neocortex. EXS 57, 212-228.